Breaking News Instant updates and real-time market news.

BPMC

Blueprint Medicines

$29.37

-0.97 (-3.20%)

18:04
11/30/16
11/30
18:04
11/30/16
18:04

Blueprint Medicines reports 'promising' proof-of-concept data from BLU-285 trial

Blueprint Medicines announced data from its ongoing Phase 1 clinical trial evaluating BLU-285, an investigational medicine for the treatment of patients with advanced gastrointestinal stromal tumors. These data provide proof-of-concept for BLU-285, a potent, highly selective inhibitor of D842V mutant PDGFRalpha and Exon 17 mutant KIT. The data will be presented on Thursday, December 1, 2016 at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Munich, Germany. "The clinical activity observed to date in the dose escalation portion of this Phase 1 study is promising," said Michael Heinrich, M.D., Oregon Health & Science University, an investigator for the clinical trial. "Advanced GIST is a devastating illness, marked by rapid disease progression. Seeing tumor shrinkage in 14 out of 15 PDGFRalpha-driven GIST patients at this point in the study is notable. I am also excited to see tumor shrinkage in four out of the six KIT-driven GIST patients treated at the higher dose levels, indicating the potential for increased clinical activity as we continue to dose-escalate. Given these encouraging early data for this investigational medicine, I believe BLU-285 could be transformative for patients with advanced GIST." BLU-285 is currently being evaluated in the dose escalation stage of a Phase 1 clinical trial in patients with unresectable PDGFRalpha-driven GIST and patients with treatment-resistant KIT-driven GIST. As of the data cutoff date of November 1, 2016, 36 patients had been treated in the dose escalation portion of the Phase 1 clinical trial at seven dose levels, including 18 patients with PDGFRalpha-driven GIST and 18 patients with KIT-driven GIST. The median age was 61, and the median number of prior tyrosine-kinase inhibitor regimens was 3.5. As of the data cutoff date of November 1, 2016, BLU-285 was observed to be well-tolerated at all doses. The majority of adverse events (AEs) reported by investigators were Grade 1 or 2. Across all grades, AEs reported by investigators most commonly included nausea, vomiting, peripheral edema, fatigue and constipation. Investigators reported treatment-related Grade 3 AEs in three patients: nausea and vomiting; anemia and intratumoral hemorrhage; and hypophosphatemia. No dose-limiting toxicities or drug-related Grade 4 or 5 AEs were reported, and no patients discontinued BLU-285 due to treatment-related adverse events. A maximum tolerated dose has not been reached, and enrollment in the dose escalation portion of the Phase 1 clinical trial is ongoing. Based on the favorable safety profile and encouraging clinical activity observed to date in the Phase 1 clinical trial for BLU-285 for the treatment of advanced GIST, Blueprint Medicines will continue to enroll patients in the dose escalation portion of this clinical trial until a MTD or a lower recommended dose for further clinical evaluation has been established. Enrollment in the expansion cohorts for this Phase 1 clinical trial is expected to begin in the first half of 2017. Blueprint Medicines plans to enroll approximately 35 patients with advanced GIST in the expansion cohorts. We also plan to accelerate our evaluation of expanded development options for BLU-285 in GIST, including opportunities to move to earlier lines of therapy and possible combinations.

  • 01

    Dec

  • 03

    Dec

  • 05

    Dec

BPMC Blueprint Medicines
$29.37

-0.97 (-3.20%)

05/27/16
RAJA
05/27/16
INITIATION
Target $23
RAJA
Outperform
Blueprint Medicines initiated with an Outperform at Raymond James
Raymond James analyst Chris Raymond initiated Blueprint Medicines with an Outperform rating and $23 price target. The analyst thinks Blueprint's unique kinase inhibitor discovery platform is well-positioned to generate novel compounds for years to come. Coupling this with a clinical stage pipeline that remains wholly-owned, key proof-of-concept data for two products,BLU-285 and BLU-554, in three different indications by year end 2015, and a valuation offering favorable risk/reward.
08/05/16
ADAM
08/05/16
INITIATION
Target $26
ADAM
Buy
Blueprint Medicines initiated with a Buy at Canaccord
Canaccord analyst Arlinda Lee initiated Blueprint Medicines with a Buy and $26 price target.
11/11/16
ADAM
11/11/16
NO CHANGE
Target $35
ADAM
Buy
Blueprint Medicines price target raised to $35 from $26 at Canaccord
Canaccord analyst Arlinda Lee raised her target on Blueprint Medicines to $35 from $26 following company updates on its pipeline of novel, rationally designed, target kinase inhibitors. The analyst increased her probability of success for the company's three programs to 25% from 20% and maintained her Buy rating on Blueprint Medicines shares.
11/29/16
WEDB
11/29/16
NO CHANGE
WEDB
Blueprint Medicines data 'highly encouraging,' says Wedbush
Wedbush analyst David Nierengarten says that Phase I data on Blueprint's BLU-554 for advanced HCC was "highly encouraging." The analyst says that the drug performed well compared with approved HCC therapies. Specifically, he believes that the 10% overall response rate and the fact that four out of ten patients showed radiographic tumor reductions are "promising" signs. The analyst reiterates a $41 price target and an Outperform rating on the stock.

TODAY'S FREE FLY STORIES

IONS

Ionis Pharmaceuticals

$46.90

2.31 (5.18%)

07:09
02/28/17
02/28
07:09
02/28/17
07:09
Earnings
Ionis Pharma reports Q4 GAAP EPS 21c, may not compare with consensus (12c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

SAR

Saratoga Investment

$22.22

-0.63 (-2.76%)

07:09
02/28/17
02/28
07:09
02/28/17
07:09
Hot Stocks
Saratoga Investment raises quarterly dividend to 46c per share »

Saratoga Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDCO

The Medicines Co.

$53.22

1.16 (2.23%)

07:08
02/28/17
02/28
07:08
02/28/17
07:08
Earnings
The Medicines Co. reports Q4 adjusted EPS ($1.19), consensus ($1.43) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

FEYE

FireEye

$11.50

0.26 (2.31%)

, PI

Impinj

$29.12

-0.87 (-2.90%)

07:08
02/28/17
02/28
07:08
02/28/17
07:08
Conference/Events
Pacific Crest to hold a summit »

12th Annual Pacific Crest…

FEYE

FireEye

$11.50

0.26 (2.31%)

PI

Impinj

$29.12

-0.87 (-2.90%)

BL

BlackLine

$29.56

-0.36 (-1.20%)

FB

Facebook

$136.41

0.97 (0.72%)

MB

MINDBODY

$27.05

1.1 (4.24%)

PCTY

Paylocity

$36.41

-0.37 (-1.01%)

AZPN

Aspen Technology

$59.00

0.63 (1.08%)

ECOM

ChannelAdvisor

$10.75

-0.4 (-3.59%)

DATA

Tableau

$53.58

0.32 (0.60%)

CTXS

Citrix

$80.16

-0.02 (-0.02%)

GRPN

Groupon

$4.49

0.02 (0.45%)

CYBR

CyberArk

$50.60

0.07 (0.14%)

PFPT

Proofpoint

$79.35

-0.29 (-0.36%)

WDAY

Workday

$90.19

0.53 (0.59%)

ULTI

Ultimate Software

$199.17

0.81 (0.41%)

AMBR

Amber Road

$7.75

-0.1 (-1.27%)

VEEV

Veeva

$44.14

-0.07 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 02

    Mar

  • 05

    Mar

  • 06

    Mar

  • 07

    Mar

  • 08

    Mar

  • 09

    Mar

  • 10

    Mar

  • 13

    Mar

  • 14

    Mar

  • 19

    Mar

  • 22

    Mar

  • 23

    Mar

  • 24

    Mar

  • 28

    Mar

SXL

Sunoco Logistics

$25.23

-0.04 (-0.16%)

07:08
02/28/17
02/28
07:08
02/28/17
07:08
Initiation
Sunoco Logistics initiated  »

Sunoco Logistics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WDAY

Workday

07:08
02/28/17
02/28
07:08
02/28/17
07:08
Downgrade
Workday rating change  »

Workday downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 02

    Mar

  • 13

    Mar

  • 14

    Mar

NXST

Nexstar

$70.20

0.45 (0.65%)

07:07
02/28/17
02/28
07:07
02/28/17
07:07
Earnings
Nexstar reports Q4 EPS 64c including items, consensus $1.38 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 06

    Mar

VRX

Valeant

$16.71

0.53 (3.28%)

07:07
02/28/17
02/28
07:07
02/28/17
07:07
Hot Stocks
Valeant CEO says 'well poised for turnaround in 2017' »

"Today, we announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 02

    Mar

  • 14

    Mar

ROYT

Pacific Coast Oil

$1.94

0.02 (1.04%)

07:07
02/28/17
02/28
07:07
02/28/17
07:07
Downgrade
Pacific Coast Oil rating change  »

Pacific Coast Oil…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XXII

22nd Century

$0.96

-0.016 (-1.63%)

07:06
02/28/17
02/28
07:06
02/28/17
07:06
Hot Stocks
22nd Century receives feedback from FDA regarding MRTP application »

22nd Century Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NYLD

NRG Yield

$17.55

-0.19 (-1.07%)

07:05
02/28/17
02/28
07:05
02/28/17
07:05
Hot Stocks
NRG Yield reconfirms 2017 outlook »

NRG Yield is reconfirming…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

TA

TravelCenters

$7.45

0.15 (2.05%)

07:05
02/28/17
02/28
07:05
02/28/17
07:05
Earnings
TravelCenters reports Q4 EPS (17c), consensus (6c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

METC

Ramaco Resources

$10.89

-0.03 (-0.27%)

07:05
02/28/17
02/28
07:05
02/28/17
07:05
Initiation
Ramaco Resources initiated  »

Ramaco Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$41.82

-0.54 (-1.27%)

07:05
02/28/17
02/28
07:05
02/28/17
07:05
Hot Stocks
AT&T, Bridge Alliance enter collaboration »

AT&T and members of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

NYLD

NRG Yield

$17.55

-0.19 (-1.07%)

07:04
02/28/17
02/28
07:04
02/28/17
07:04
Earnings
NRG Yield reports Q4 net loss ($126M), adjusted EBITDA $207M »

The company said the Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

VRX

Valeant

$16.71

0.53 (3.28%)

07:04
02/28/17
02/28
07:04
02/28/17
07:04
Earnings
Valeant sees FY17 revenue $8.9B-$9.10B, consensus $8.97B »

Sees FY17 Adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 02

    Mar

  • 14

    Mar

SFTBF

SoftBank

$74.95

-0.93 (-1.23%)

, I

Intelsat

$5.87

1.18 (25.16%)

07:03
02/28/17
02/28
07:03
02/28/17
07:03
Hot Stocks
Breaking Hot Stocks news story on SoftBank, Intelsat »

SoftBank to capitalize…

SFTBF

SoftBank

$74.95

-0.93 (-1.23%)

I

Intelsat

$5.87

1.18 (25.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

I

Intelsat

$5.87

1.18 (25.16%)

, SFTBF

SoftBank

$74.95

-0.93 (-1.23%)

07:03
02/28/17
02/28
07:03
02/28/17
07:03
Hot Stocks
Intelsat, OneWeb announce conditional combination agreement »

Intelsat (I) and OneWeb…

I

Intelsat

$5.87

1.18 (25.16%)

SFTBF

SoftBank

$74.95

-0.93 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

SHOO

Steven Madden

$37.65

0.5 (1.35%)

07:03
02/28/17
02/28
07:03
02/28/17
07:03
Earnings
Steven Madden sees FY17 revenue $2.12-$2.18, consensus $2.20 »

Sees FY17 net sales up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

VRX

Valeant

$16.71

0.53 (3.28%)

07:03
02/28/17
02/28
07:03
02/28/17
07:03
Earnings
Valeant reports Q4 adjusted EPS $1.26, consensus $1.21 »

Reports Q4 revenue $2.4B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 02

    Mar

  • 14

    Mar

SHOO

Steven Madden

$37.65

0.5 (1.35%)

07:02
02/28/17
02/28
07:02
02/28/17
07:02
Earnings
Steven Madden reports Q4 EPS 49c, consensus 49c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

I

Intelsat

$5.87

1.18 (25.16%)

, SFTBF

SoftBank

$74.95

-0.93 (-1.23%)

07:02
02/28/17
02/28
07:02
02/28/17
07:02
Hot Stocks
Breaking Hot Stocks news story on Intelsat, SoftBank »

Intelsat, OneWeb announce…

I

Intelsat

$5.87

1.18 (25.16%)

SFTBF

SoftBank

$74.95

-0.93 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

AZO

AutoZone

$740.85

8.1 (1.11%)

07:01
02/28/17
02/28
07:01
02/28/17
07:01
Hot Stocks
AutoZone opened 33 new stores in Q2 »

During the quarter ended…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

AVT

Avnet

$46.24

-0.17 (-0.37%)

07:01
02/28/17
02/28
07:01
02/28/17
07:01
Hot Stocks
Avnet expands share repurchase program, increases dividend »

Avnet said that its Board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

AZO

AutoZone

$740.85

8.1 (1.11%)

07:00
02/28/17
02/28
07:00
02/28/17
07:00
Hot Stocks
AutoZone reports Q2 inventory up 8.7% »

The Company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.